TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01334333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus - Prograf® twice daily formulation
Description: twice daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus - Advagraf® once daily formulation
Description: once daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
Study: NCT03387176

Intervention type: OTHER
Intervention: Implementation of a gluten-free diet
Description: Patients will be placed on gluten free diet for 9-12 months.

Intervention type: OTHER
Intervention: Implementation of a gluten-free diet
Description: Patients will be placed on gluten free diet for 9-12 months.
Study: NCT03127631

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition
Description: Standardized advice on healthy diet practices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Standardized advice on exercise including strength training and resistance training exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation
Description: Advice to quit smoking, if applicable, and on available aids to quit smoking,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)
Description: Prescription for a low to moderate dose statin, such as simvastatin 10-40mg daily, atorvastatin 10-40mg daily, rosuvastatin 5-20mg daily or pravastatin 10-40mg daily.
Study: NCT04484350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine
Description: 10 - 20 mg IV bolus q20 min until systolic BP below target (max 240 mg per 24 hours)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydralazine
Description: 10 - 20 mg IV bolus q20 min until systolic BP below target (max 240 mg per 24 hours)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: 1.25 - 2.5 mg IV bolus and then q6h PRN.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: 1.25 - 2.5 mg IV bolus and then q6h PRN.
Study: NCT01583426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: nab-Paclitaxel 125 mg/m² weekly for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m² weekly for 12 weeks
Study: NCT02518555

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study: NCT00133978

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline intravenously and EN placebo formula (from Fresenius Kabi, Germany)
Study: NCT02518555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent Conjugate Vaccine
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent Conjugate Vaccine
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Vaccine
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Vaccine
Description: Given IM
Study: NCT03158402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation with inspiratory muscle training
Description: 3 to 6 weeks of two times a day inspiratory muscle training at 80% of the Maximum Inspiratory Pressure.
Study: NCT04493840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenfu Injection
Description: 80ml Shenfu Injection + 70ml 5% glucose injection, ivdrip, within 30 minutes before PCI and 1 to 5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Glucose Injection
Description: 150 ml 5% glucose injection, ivdrip, within 30 minutes before PCI and 1 to 5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
Study: NCT05428189

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Plaque Disclosing Agent
Description: A plaque disclosing agent is applied on teeth to detect plaque. Air-polishing will be used as main instrument for biofilm and stains removal, followed by ultrasonic scaling.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airpolishing and ultrasonic debridement
Description: Air-polishing will be used as main instrument for biofilm and stains removal, followed by ultrasonic scaling.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airpolishing and ultrasonic debridement
Description: Air-polishing will be used as main instrument for biofilm and stains removal, followed by ultrasonic scaling.
Study: NCT01874678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1/Cisplatin
Study: NCT01390064

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG
Description: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG
Description: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG
Description: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule
Study: NCT01529801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osseotite Certain Tapered Group A
Description: Osseotite Certain Tapered with different surface roughness

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osseotite Certain Tapered Group B
Description: Osseotite Certain Tapered with different surface roughness

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osseotite Certain Tapered Group C
Description: Osseotite Certain Tapered with different surface roughness
Study: NCT05143710

Intervention type: DIAGNOSTIC_TEST
Intervention: PRES in PE or E
Description: patients diagnosed with posterior reversible encephalopathy syndrome with preeclampsia or eclampsia
Study: NCT03680456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: maximum of 750mg in U.S. is given, maximum of 1000mg in EU

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Crystalloid
Description: an equivalent volume dose of Natriumchlorid is administered
Study: NCT02642549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Girls for Health
Description: The G4H '1000 Hours' Bridge Program will offer English, science and math training, career workshops, opportunity to 'shadow' a health provider, a mentored safe space club to facilitate economic empowerment, training on gender equity and human rights, and communication/leadership skills. Cash transfers for vacations will be provided to support participation. Girls who receive 5 credits on their SSCE exams and pass the health training institute (HTI) entrance exam are eligible for admission. A Foundational Science Training (FST) program will be provided to the '1000 Hours' participants who gain admission to a HTI to strengthen their ability to the pass the HTI weeding exams. The FST will focus on English, math and science training, and safe spaces for social support development.
Study: NCT01913587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture points are ST36, GB34 (bilateral), BL60 (bilateral), BL40 (bilateral), and 2 Back-su points (bilateral). Back-su points are selected as close as possible to pain region. Electroacupuncture will be performed at only 2 Back-su points (bilateral).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve block
Description: Epidural nerve block uses the mixture (10ml) of dexamethasone (10 mg) and bupivacaine (10 mg) dissolved in saline solution. Medial branch block uses mepivacaine (10 mg).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block
Description: Epidural nerve block uses the mixture (10ml) of dexamethasone (10 mg) and bupivacaine (10 mg) dissolved in saline solution. Medial branch block uses mepivacaine (10 mg).
Study: NCT01450904

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadriceps incision < 2 cm
Description: MIS-TKA was performed with less than 2 cm Quadriceps incision length

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadriceps incision 2-4 cm
Description: MIS-TKA was performed with 2 to 4 cm Quadriceps incision length

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadriceps incision > 4 cm
Description: MIS-TKA was performed with more than 4 cm Quadriceps incision length
Study: NCT01325220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arbaclofen
Description: 5 mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arbaclofen
Description: 10 mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arbaclofen
Description: 10 mg tid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tid
Study: NCT02524600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: myocardial IQ-SPECT imaging applied to scintigraphic imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: scintigraphic imaging
Study: NCT04065165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat Ethyl
Description: 250 mg TID orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lanreotide
Description: 120 mg Q4W deep subcutaneous injection in the superior external quadrant of the buttock or in the upper outer thigh

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Description: 120 mg Q4W deep subcutaneous injection in the superior external quadrant of the buttock or in the upper outer thigh
Study: NCT04456153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Continued standard of care therapy together with an oral dose of 1500 mg atovaquone twice daily (administered with a meal or snack) for up to 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Continued standard of care therapy together with matching placebo
Study: NCT02905396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Description: implantation of spinal cord stimulator
Study: NCT02398994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Methylprednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin
Study: NCT04173598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Adaptation Training for Caregivers (CAT Famille)
Description: Family CAT manual, with a module each week to be read according to the patient's objectives and a 15-minute webcam feedback by the psychologist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Psycho-education manual, with a weekly reading module and a 15-minute webcam feedback by the psychology student.
Study: NCT03848871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enstilar
Description: Enstilar foam applied to affected area once daily
Study: NCT03158402

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Prehabilitation with inspiratory muscle training
Description: 3 to 6 weeks of two times a day inspiratory muscle training at 80% of the Maximum Inspiratory Pressure.
Study: NCT02912663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil and Magnesium Sulfate
Description: Single dose strategy will be used

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single matching dosing strategy will be used
Study: NCT03601871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide (Thalidomide Oral Product)100 mg by mouth twice a day on days 1-5 after chemotherapy .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-HT3 antagonists
Description: Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-HT3 antagonists
Description: Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3
Study: NCT02918084

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Anastrozole or Letrozole or Exemestane
Description: Adjuvant chemotherapy → Anastrozole or Letrozole or Exemestane once a day for 5 years (sequential arm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole or Letrozole or Exemestane
Description: Adjuvant chemotherapy + Anastrozole or Letrozole or Exemestane once a day for 5 years (concurrent arm)
Study: NCT02623179

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: culture versus Molecular diagnostics
Description: Treatment based on the results of the FH C \& S testing - Odd Numbers on randomization table

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: culture versus Molecular diagnostics
Description: Treatment based on the results of the FH C \& S testing - Odd Numbers on randomization table
Study: NCT03127631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE inhibitor
Description: Prescription for an ACE-I (preferable) or an angiotensin receptor blocker for baseline systolic blood pressure greater \>130mmHg, or other blood pressure lowering medication as applicable.
Study: NCT04233489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Description: FNI is a family based intervention that facilitates and strengthens the mother-infant emotional connection through a structured guided interaction by a physician.~The mother is asked to sit with her baby in her arms so that they are face-to-face, and when the baby becomes restless, the physician will coach the mom to bring the baby back to a calm state. The mother will also be encouraged to verbalize her feelings to her baby. Mother-infant emotional connection is known to affect various developmental processes and improve overall health. FNI was previously shown to be efficacious in improving several long-term health outcomes in preterm infants in the neonatal intensive care unit (NICU).
Study: NCT03737825

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computerized gaming rehabilitation Program 1
Description: Brain training games displayed on a large screen paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching in place.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Computerized gaming rehabilitation Program 2
Description: Brain training games displayed on a tablet device paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching.
Study: NCT01649700

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous adipose-derived mesenchymal stem cells
Description: Patients will receive five infusions, one month apart, each comprising 5-7x10\^7 cells of autologous adipose-derived mesenchymal stem cells.
Study: NCT03669978

Intervention type: PROCEDURE
Intervention: Creation of a bone and arterial panorama using EndoNaut® software.
Description: The routine care procedure begins with staged injections of contrast medium to provide a map of the lesions. The lesions are then treated by angioplasty with or without stenting.~New injections of contrast product are made to control the results of the treatment.~As part of this pilot study, the assistive software and its interface will be linked and with the mobile C-arm X-ray system. Scopic images and angiograms will be retransmitted to be processed by the EndoNaut® software.
Study: NCT03698201

Intervention type: OTHER
Intervention: Non-interventional
Description: Translational, observational study

Intervention type: OTHER
Intervention: Non-interventional
Description: Translational, observational study
Study: NCT02852525

Intervention type: DEVICE
Group type: OTHER
Intervention: Confocal laser endomicroscopy (pCLE)
Description: Patients agreeing to participate in the research study will receive an additional intravenous injection during endoscopy. This dose of 2.5 mg of IV fluorescein will be administered during their EGD. Probe-based microscopy will be used to evaluate the mucosa of the esophagus and GE junction
Study: NCT02479347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Preoperative skin preparation with tinted chlorhexidine gluconate 2% in 70% isopropyl alcohol administered with single-dose applicator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Description: Preoperative skin preparation with povidone-iodine 10% aqueous solution
Study: NCT01562028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Patients will be treated with erlotinib, 150 mg p.o., daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients will be treated with bevacizumab 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days)
Study: NCT03537664

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Root canal preparation
Description: First endodontic treatment session includes the root canal preparation with Reciproc System and NaOCl 2.5%, followed by final irrigation protocol using activation techniques: XP Endo-Finisher and ultrasonic activation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal preparation
Description: First endodontic treatment session includes the root canal preparation with Reciproc System and NaOCl 2.5%, followed by final irrigation protocol using activation techniques: XP Endo-Finisher and ultrasonic activation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracanal medication
Description: The second endodontic treatment includes the intracanal medication with calcium hydroxide paste, followed by an 2nd-visit root canal preparation
Study: NCT01082276

Intervention type: DRUG
Group type: OTHER
Intervention: Lurasidone HCl
Description: 40mg, Single-dose of lurasidone 40 mg (one 40 mg tablet) on Day 1. Daily dosing of rifampin 600 mg (two 300 mg capsules) on Days 1-8. On Day 8, subjects will also receive a single-dose of lurasidone 40 mg (one 40 mg tablet).
Study: NCT01479348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]-5-FLUORO-2'-DEOXYCYTIDINE
Description: 18FdCyd radiotracer
Study: NCT03109912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized-Coaching Interventions
Description: At the baseline fitness assessment, participants receive exercise prescriptions based upon their individual assessment. One of the ultimate exercise prescription goals is to achieve 30-minutes of an endurance-style exercise 5 times/week which may vary depending upon baseline fitness assessment. Aside from team sports, endurance-style exercise prescriptions may include simply walking, jump roping or stair climbing to more complex Tabata-style workouts. Two additional physical therapy (PT) 30-minute appointments are scheduled about 4-6 weeks and 8-10 weeks from enrollment. These 30-minute PT follow-up appointments will vary based on initial assessment and previous exercise prescription success but will include strength training for major muscles groups and/or flexibility exercises with yoga as well as reinforcement of previously learned techniques. PT will add additional individualized recommendations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Messages
Description: Intervention participants are enrolled to receive motivational messages starting 14 days after enrollment via preferred contact method (SMS, telephone call and/or email) every 3-4 days over the 6-month study period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Exercise Tutorials
Description: Participants are given access to Do More, B'More, Live Fit webpage which includes spotlighted exercises, instructional exercise photos and videos.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support and Peer Challenges
Description: Participants are invited to join the Do More, B'More, Live Fit Activity Group via the FitBit Dashboard and are invited to friend the study team members and other exercise-intervention participants in order to take part in FitBit step-goal challenges.
Study: NCT00466492

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sedation or no sedation during mechanical ventilation
Description: No sedation to critically ill patients
Study: NCT04066764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: 15mg twice daily for 3 weeks after operation, later 20mg once daily until 3 months after the filter is removed. Application: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: 3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until until 3 months after the filter is removed. Frequency: once daily Application: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadroparin
Description: Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous